Cargando…

Alglucosidase alfa: 5 years of experience in late-onset Pompe disease

Detalles Bibliográficos
Autor principal:	Schoser, Benedikt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667046/ http://dx.doi.org/10.1186/1471-2474-14-S2-O9

Ejemplares similares

Long-Term Experience with Anaphylaxis and Desensitization to Alglucosidase Alfa in Pompe Disease
por: Ertoy Karagol, Hacer Ilbilge, et al.
Publicado: (2023)

Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
por: Beck, Michael
Publicado: (2009)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021)

A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease
por: Zhu, Diqi, et al.
Publicado: (2022)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa
por: Baek, Rena C., et al.
Publicado: (2016)

Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
por: Dimachkie, Mazen M., et al.
Publicado: (2022)

The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
por: Lachmann, Robin, et al.
Publicado: (2013)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
por: Wenninger, Stephan, et al.
Publicado: (2021)

Pregnancy in Pompe disease
por: Plöckinger, Ursula
Publicado: (2013)

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
por: Byrne, Barry J., et al.
Publicado: (2017)

Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study
por: van Gelder, C. M., et al.
Publicado: (2016)

Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Limitations of muscle biopsy in Pompe disease
por: Vissing, John
Publicado: (2013)

Walking delay as leading symptom in late-onset Pompe disease
por: Gökce, S, et al.
Publicado: (2013)

Advances in imaging for the diagnosis and disease monitoring of Pompe disease
por: Carlier, Robert-Yves
Publicado: (2013)

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial
por: Kishnani, Priya S., et al.
Publicado: (2023)

Long term outcome and clinical experience on immune tolerance induction therapies in infantile Pompe disease
por: Austin, Stephanie, et al.
Publicado: (2013)

Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV
por: Yi, Haiqing, et al.
Publicado: (2016)

Hypothyroidism in late-onset Pompe disease
por: Schneider, Joseph, et al.
Publicado: (2016)

S1.5 Role of the pulmonologist in the late-onset Pompe disease
por: Fiorentino, Giuseppe, et al.
Publicado: (2011)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Small fiber involvement is independent from clinical pain in late-onset Pompe disease
por: Enax-Krumova, Elena K., et al.
Publicado: (2022)

Late-Onset Pompe Disease with Nemaline Bodies
por: Frezza, E., et al.
Publicado: (2018)

Late-onset Pompe disease manifests in the brain
por: Finsterer, Josef
Publicado: (2019)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α
por: Kishnani, Priya, et al.
Publicado: (2017)

Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease
por: Tiraboschi, Gilles, et al.
Publicado: (2023)

Fatigue: an important feature of late-onset Pompe disease
por: Hagemans, M. L. C., et al.
Publicado: (2007)

Bone density in patients with late onset Pompe disease
por: Papadimas, George, et al.
Publicado: (2012)

Response: Late-onset Pompe disease manifests in the brain
por: Schneider, Ilka, et al.
Publicado: (2019)

Is the brain involved in patients with late‐onset Pompe disease?
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Treatment Dilemma in Children with Late-Onset Pompe Disease
por: Faraguna, Martha Caterina, et al.
Publicado: (2023)

A Comprehensive Update on Late-Onset Pompe Disease
por: Labella, Beatrice, et al.
Publicado: (2023)

Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus
por: Fatehi, Farzad, et al.
Publicado: (2021)

Diflunisal in late-onset FAP patients with moderate to severe neuropathy
por: Obici, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h52h380ubclvapk6fjq2c9egub